AstraZeneca PLC (AZN)vsiRhythm Technologies Inc (IRTC)
AZN
AstraZeneca PLC
$184.74
-1.40%
HEALTHCARE · Cap: $287.11B
IRTC
iRhythm Technologies Inc
$129.16
+6.96%
HEALTHCARE · Cap: $3.97B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 7762% more annual revenue ($58.74B vs $747.14M). AZN leads profitability with a 17.4% profit margin vs -6.0%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
IRTC
Avoid31
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+4.1%
Fair Value
$214.51
Current Price
$184.74
$29.77 discount
Margin of Safety
-55.9%
Fair Value
$97.56
Current Price
$129.16
$31.60 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
Revenue surging 27.1% year-over-year
Areas to Watch
Expensive relative to growth rate
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
0.0% earnings growth
Operating margin of 4.2%
Trading at 27.3x book value
ROE of -36.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bull Case : IRTC
The strongest argument for IRTC centers on Revenue Growth. Revenue growth of 27.1% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.
Bear Case : IRTC
The primary concerns for IRTC are EPS Growth, Operating Margin, Price/Book.
Key Dynamics to Monitor
AZN profiles as a value stock while IRTC is a growth play — different risk/reward profiles.
IRTC carries more volatility with a beta of 1.18 — expect wider price swings.
IRTC is growing revenue faster at 27.1% — sustainability is the question.
AZN generates stronger free cash flow (1.4B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 31/100), backed by strong 17.4% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
iRhythm Technologies Inc
HEALTHCARE · MEDICAL DEVICES · USA
iRhythm Technologies, Inc., a digital healthcare company, offers ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. The company is headquartered in San Francisco, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?